MCID: KRT006
MIFTS: 55

Keratoconjunctivitis

Categories: Eye diseases

Aliases & Classifications for Keratoconjunctivitis

MalaCards integrated aliases for Keratoconjunctivitis:

Name: Keratoconjunctivitis 12 56 45 15 74

Classifications:



External Ids:

Disease Ontology 12 DOID:9368
ICD9CM 36 370.40
MeSH 45 D007637
NCIt 51 C34744
SNOMED-CT 69 88151007
ICD10 34 H16.2 H16.20
UMLS 74 C0022573

Summaries for Keratoconjunctivitis

MalaCards based summary : Keratoconjunctivitis is related to keratoconjunctivitis sicca and vernal keratoconjunctivitis. An important gene associated with Keratoconjunctivitis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Tacrolimus and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and thyroid, and related phenotypes are hematopoietic system and digestive/alimentary

Wikipedia : 77 Keratoconjunctivitis is inflammation ("-itis") of the cornea and... more...

Related Diseases for Keratoconjunctivitis

Diseases related to Keratoconjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 366)
# Related Disease Score Top Affiliating Genes
1 keratoconjunctivitis sicca 33.9 IL4 NGF TNF
2 vernal keratoconjunctivitis 33.8 CCL11 ICAM1 IL13 IL4 IL5 RNASE3
3 atopic keratoconjunctivitis 33.3 IFNG IL2 IL3 IL4 IL5 RNASE3
4 graft-versus-host disease 30.6 IFNG IL2 TNF
5 chlamydia 30.4 CXCL8 IFNG IL4 TNF
6 acquired immunodeficiency syndrome 30.3 IFNG IL2 TNF
7 papillary conjunctivitis 30.2 CCL11 CXCL8 IL4
8 uveitis 30.2 ICAM1 IFNG IL4 TNF
9 lichen planus 30.2 ICAM1 IFNG IL4 TNF
10 graves' disease 30.1 ICAM1 IFNG IL4
11 diphtheria 30.0 IL13 IL2 IL3
12 giant papillary conjunctivitis 29.9 CCL11 CXCL8 IL4 RNASE3
13 cellulitis 29.8 IL5 RNASE3 TNF
14 measles 29.8 CD46 IFNG IL2 IL4
15 human immunodeficiency virus type 1 29.8 CCL11 IFNG IL2 TNF
16 ocular cicatricial pemphigoid 29.8 IL4 NGF RNASE3
17 sleep apnea 29.8 CXCL8 ICAM1 TNF
18 sinusitis 29.8 CXCL8 IL5 RNASE3
19 peritonitis 29.8 CXCL8 ICAM1 TNF
20 alopecia areata 29.7 ICAM1 IFNG IL2 TNF
21 rheumatoid arthritis 29.6 CXCL8 ICAM1 IFNG IL2 IL4 TNF
22 tetanus 29.6 IFNG IL13 IL2 IL4 IL5
23 conjunctivitis 29.6 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
24 common variable immunodeficiency 29.6 IFNG IL2 IL4 IL5 TNF
25 colitis 29.6 CXCL8 IFNG IL2 IL4 TNF
26 erythema multiforme 29.4 CCL17 ICAM1 IFNG IL2 TNF
27 allergic conjunctivitis 29.4 CCL11 CXCL8 ICAM1 IFNG IL13 IL4
28 otitis media 29.4 CCL11 CXCL8 IL4 RNASE3 TNF
29 pleurisy 29.3 CXCL8 ICAM1 IFNG IL2 TNF
30 neuritis 29.3 IFNG IL4 TNF
31 dermatitis 29.2 CCL11 CCL17 IFNG IL13 IL4 IL5
32 rhinitis 28.8 CCL11 CXCL8 ICAM1 IL13 IL4 IL5
33 contact dermatitis 28.6 CCL17 CXCL8 ICAM1 IFNG IL4 IL5
34 allergic rhinitis 28.6 CCL11 CXCL8 ICAM1 IFNG IL13 IL4
35 allergic asthma 28.2 CCL11 CCL17 IFNG IL13 IL4 IL5
36 dermatitis, atopic 27.4 CCL11 CCL17 CXCL8 ICAM1 IFNG IL13
37 asthma 26.7 CCL11 CCL17 CXCL8 ICAM1 IFNG IL13
38 superior limbic keratoconjunctivitis 12.6
39 punctate epithelial keratoconjunctivitis 12.2
40 neurotrophic keratoconjunctivitis 12.1
41 sjogren syndrome 12.0
42 phlyctenulosis 11.9
43 shipyard eye 11.9
44 acute contagious conjunctivitis 11.6
45 dry eye syndrome 11.4
46 exposure keratitis 11.2
47 myelopathy, htlv-1-associated 11.0
48 aplasia of lacrimal and salivary glands 11.0
49 tropical spastic paraparesis 11.0
50 retrovirus-associated myelopathy 11.0

Comorbidity relations with Keratoconjunctivitis via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Keratoconjunctivitis:



Diseases related to Keratoconjunctivitis

Symptoms & Phenotypes for Keratoconjunctivitis

MGI Mouse Phenotypes related to Keratoconjunctivitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.02 CCL11 CCL17 ICAM1 IFNG IL13 IL2
2 digestive/alimentary MP:0005381 9.97 ICAM1 IFNG IL13 IL2 IL4 IL5
3 immune system MP:0005387 9.96 CCL11 CCL17 ICAM1 IFNG IL13 IL2
4 integument MP:0010771 9.7 ICAM1 IFNG IL13 IL4 NGF TNF
5 respiratory system MP:0005388 9.56 CCL11 IFNG IL13 IL2 IL4 IL5
6 vision/eye MP:0005391 9.23 AOC1 CD46 ICAM1 IFNG IL2 IL4

Drugs & Therapeutics for Keratoconjunctivitis

Drugs for Keratoconjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 262)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 104987-11-3 445643 439492 6473866
2
Tocopherol Approved, Investigational Phase 4,Not Applicable 1406-66-2 14986
3
Povidone Approved Phase 4,Not Applicable 9003-39-8
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
5
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9004-61-9 53477741
6
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 82034-46-6, 129260-79-3 444025 9865442
7
Tobramycin Approved, Investigational Phase 4,Not Applicable 32986-56-4 5496 36294
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-02-2 5743
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1177-87-3
10
Iodine Approved, Investigational Phase 4,Not Applicable 7553-56-2 807
11
Glycerol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 56-81-5 753
12
Fluorometholone Approved, Investigational Phase 4,Phase 3,Not Applicable 426-13-1 9878
13
Histamine Approved, Investigational Phase 4,Phase 3 51-45-6 774
14
Povidone-iodine Approved Phase 4 25655-41-8
15
Ganciclovir Approved, Investigational Phase 4,Phase 2,Not Applicable 82410-32-0 3454
16
Lifitegrast Approved Phase 4,Phase 3,Phase 2,Not Applicable 1025967-78-5
17
Menthol Approved Phase 4 2216-51-5 16666
18
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 32051
19
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
20
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
21
Dimenhydrinate Approved Phase 4,Not Applicable 523-87-5 441281
22
Azithromycin Approved Phase 4 83905-01-5 55185 447043
23
Ketorolac Approved Phase 4,Phase 2 66635-83-4, 74103-06-3 3826
24
Dipivefrin Approved Phase 4,Phase 1 52365-63-6 3105
25
Ofloxacin Approved Phase 4 82419-36-1 4583
26
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
27
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3 302-25-0
28
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
29
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3 2921-57-5
30
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
31
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
32
Sorbitol Approved Phase 4 50-70-4 5780
33
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-02-9 14985
34
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 1406-16-2
35
Vitamin D3 Approved, Nutraceutical Phase 4,Not Applicable 67-97-0 5280795 6221
36
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
37
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Not Applicable 8001-79-4
38
Glutamic Acid Approved, Nutraceutical Phase 4 56-86-0 33032
39
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
40 Tocotrienol Investigational Phase 4,Not Applicable 6829-55-6
41
Bromfenac Approved July 1997 Phase 4,Phase 3,Phase 2 91714-94-2 60726
42
Prednisolone hemisuccinate Experimental Phase 4,Phase 3 2920-86-7
43 Rebamipide Investigational Phase 4,Phase 3,Phase 2,Phase 1 90098-04-7
44 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Omega 3 Fatty Acid Phase 4,Phase 2,Phase 3,Not Applicable
50 Tocotrienols Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 547)
# Name Status NCT ID Phase Drugs
1 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
2 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity Unknown status NCT02992535 Phase 4
3 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
4 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
5 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
6 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
7 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
8 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
9 A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Completed NCT03464435 Phase 4 Tacrolimus
10 Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
11 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4 N-acetyl-aspartyl-glutamate (NAAXIA Sine)
12 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4 2% povidone-iodine;2% povidone-iodine
13 A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Completed NCT02139033 Phase 4 Retaine™
14 A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
15 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
16 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
17 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4 Lotemax;Restasis
18 Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness Completed NCT03686878 Phase 4 Lifitegrast
19 Comparative Study of Rohto Dry-Aid® and Systane® Ultra in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
20 Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) Completed NCT02985827 Phase 4 Rohto (r) Hydra;Systane (r) Ultra
21 A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye Completed NCT02951910 Phase 4
22 Comparison of Autologous Serum Versus Preservative Free Artificial Tear Completed NCT02752763 Phase 4 %40 diluted Autologous serum;Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
23 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN) Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
24 Tear Lipid Layer Thickness With Emollient Eye Drops Completed NCT03380624 Phase 4 Refresh Optive;Refresh Optimum OMEGA 3
25 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
26 Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
27 Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops Completed NCT02758327 Phase 4 TheraTears Lubricating Eye Drops
28 Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis® Completed NCT02554981 Phase 4 Cyclosporine 0.05% Ophthalmic Emulsion
29 Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye Completed NCT01105910 Phase 4
30 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE) Completed NCT01105624 Phase 4 azithromycin ophthalmic solution, 1%;Visine® for Contacts®
31 Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects Completed NCT01086774 Phase 4
32 A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens Completed NCT01061268 Phase 4 No topical artificial tear;Blink® Tears Lubricant Eye Drops
33 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Completed NCT00938704 Phase 4 carboxymethylcellulose 0.5% +glycerin 0.9%;sodium hyaluronate 0.18%
34 Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy Completed NCT02121847 Phase 4 cyclosporine 0.05% ophthalmic emulsion;carboxymethylcellulose-based lubricant eye drops
35 Kynex Versus Refresh Plus Study in Subject With Dry Eye Completed NCT00809198 Phase 4
36 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
37 Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms Completed NCT00761202 Phase 4 A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®;Sodium hyaluronate
38 Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects Completed NCT01970917 Phase 4
39 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
40 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality Completed NCT00622037 Phase 4 PEG-400 based artificial tear;Systane
41 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). Completed NCT00620893 Phase 4 PEG- 400 based artificial tear;Systane
42 Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes Completed NCT00469573 Phase 4 1. Optive
43 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4 Restasis, Optive Tears
44 A Comparison of Optive in Patients Previously Using Systane for the Treatment of Dry Eye Completed NCT00399230 Phase 4 Optive
45 Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00399061 Phase 4 Systane, Optive, Restasis
46 Comparison of Systane Free vs. Saline in the Treatment of Dry Eye Completed NCT00388791 Phase 4 Systane Free
47 Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Completed NCT00386646 Phase 4 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
48 Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4 Cyclosporine, Refresh Plus
49 The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Completed NCT01280110 Phase 4 Hydroxypropylmethylcellulose;Carboxymethylcellulose
50 Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Completed NCT01198782 Phase 4

Search NIH Clinical Center for Keratoconjunctivitis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: keratoconjunctivitis

Genetic Tests for Keratoconjunctivitis

Anatomical Context for Keratoconjunctivitis

MalaCards organs/tissues related to Keratoconjunctivitis:

42
Eye, Testes, Thyroid, Salivary Gland, T Cells, Bone, Skin

Publications for Keratoconjunctivitis

Articles related to Keratoconjunctivitis:

(show top 50) (show all 1802)
# Title Authors Year
1
The efficacy of 0.1% tacrolimus ophthalmic suspension in the treatment of severe atopic keratoconjunctivitis. ( 30639466 )
2019
2
Tacrolimus ointment in the management of atopic keratoconjunctivitis. ( 30851973 )
2019
3
Chlamydia pecorum Associated With an Outbreak of Infectious Keratoconjunctivitis in Semi-domesticated Reindeer in Sweden. ( 30805351 )
2019
4
Thymic Stromal Lymphopoietin-Related Allergic Pathway in Patients With Vernal Keratoconjunctivitis. ( 30601284 )
2019
5
Human adenoviral type 54 keratoconjunctivitis accompanied by stellate keratitis and keratic precipitates: two cases. ( 30616635 )
2019
6
Hyperacute Gonococcal Keratoconjunctivitis. ( 30652276 )
2019
7
Challenges in management of epidemic keratoconjunctivitis with emerging recombinant human adenoviruses. ( 30654207 )
2019
8
Monotherapy of topical tacrolimus 0.03% in the treatment of vernal keratoconjunctivitis in the pediatric population. ( 30664932 )
2019
9
Therapeutic effects of Houttuynia eye drops combined with olopatadine hydrochloride eye drops on vernal keratoconjunctivitis. ( 30679995 )
2019
10
Long-term use of topical tacrolimus ointment: a safe and effective option for the treatment of vernal keratoconjunctivitis. ( 30698232 )
2019
11
Equine eosinophilic keratoconjunctivitis in California: retrospective study of 47 eyes from 29 cases (1993-2017). ( 30706617 )
2019
12
Assessment of meibomian gland morphology by noncontact infrared meibography in Shih Tzu dogs with or without keratoconjunctivitis sicca. ( 30715776 )
2019
13
Comparative efficacy of topical oclacitinib 0.1% and tacrolimus 0.01% in canine keratoconjunctivitis sicca. ( 30724448 )
2019
14
Apricot Kernel Extract and Amygdalin Inhibit Urban Particulate Matter-Induced Keratoconjunctivitis Sicca. ( 30759852 )
2019
15
Evaluation of adenovirus amplified detection of immunochromatographic test using tears including conjunctival exudate in patients with adenoviral keratoconjunctivitis. ( 30826875 )
2019
16
Vitamin D serum levels in children with vernal keratoconjunctivitis and disease control. ( 30843446 )
2019
17
Dermatologic tacrolimus ointment on the eyelids for steroid-refractory vernal keratoconjunctivitis. ( 30852635 )
2019
18
Severe mycotic keratoconjunctivitis caused by Fusarium sp. in an immunocompetent child successfully treated with intravenous voriconazole and keratoplasty: case report and short review of the literature. ( 30891242 )
2019
19
Atopic keratoconjunctivitis: A diagnostic dilemma-a case report. ( 29668589 )
2018
20
Infectious keratoconjunctivitis in semi-domesticated Eurasian tundra reindeer (Rangifer tarandus tarandus): microbiological study of clinically affected and unaffected animals with special reference to cervid herpesvirus 2. ( 29338721 )
2018
21
Assessment of corneal and conjunctival metaplasia by impression cytology during the treatment of canine keratoconjunctivitis sicca. ( 29958527 )
2018
22
Recalcitrant Atopic Keratoconjunctivitis in Children: A Case Report and Literature Review. ( 29610174 )
2018
23
High Inflammatory Infiltrate Correlates With Poor Symptomatic Improvement After Surgical Treatment for Superior Limbic Keratoconjunctivitis. ( 29346129 )
2018
24
Adenovirus-related epidemic keratoconjunctivitis outbreak at a hospital-affiliated ophthalmology clinic. ( 29305276 )
2018
25
Corneal staining patterns in vernal keratoconjunctivitis: the new VKC-CLEK scoring scale. ( 29367201 )
2018
26
Epidemic Keratoconjunctivitis: (Superficial Punctate Keratitis, Keratitis Subepithelialis, Keratitis Maculosa, Keratitis Nummularis) With a Review of the Literature and a Report of 125A Cases. ( 29793576 )
2018
27
Immunohistochemical evaluation of lymphocyte populations in the nictitans glands of normal dogs and dogs with keratoconjunctivitis sicca. ( 29445621 )
2018
28
Efficacy of HL036 versus Cyclosporine A in the Treatment of Naturally Occurring Canine Keratoconjunctivitis Sicca. ( 29634381 )
2018
29
Epidemic keratoconjunctivitis cases resulting from adenovirus type 8 and 54 detected at Fukuoka University Hospital between 2014 and 2015. ( 29709978 )
2018
30
Increased Lacrimal Fluid Level of HMGB1 in Vernal Keratoconjunctivitis. ( 29847189 )
2018
31
Autonomic reinnervation and functional regeneration in autologous transplanted submandibular glands in patients with severe keratoconjunctivitis sicca. ( 29695713 )
2018
32
Anterior segment optical coherence tomography of microsporidial keratoconjunctivitis. ( 29676317 )
2018
33
Determinants of Outcomes of Adenoviral Keratoconjunctivitis. ( 29602567 )
2018
34
Re: Topical Tacrolimus for Corneal Subepithelial Infiltrates Secondary to Adenoviral Keratoconjunctivitis. ( 29664748 )
2018
35
Topical Tacrolimus 0.03% for Maintenance Therapy in Steroid-Dependent, Recurrent Phlyctenular Keratoconjunctivitis. ( 29309358 )
2018
36
Clinical Severity Classification using Automated Conjunctival Hyperemia Analysis Software in Patients with Superior Limbic Keratoconjunctivitis. ( 29336627 )
2018
37
Vernal keratoconjunctivitis in human immunodeficiency virus - The possible role of T-helper 1-T-helper 2 shift. ( 29941754 )
2018
38
Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast. ( 29958030 )
2018
39
SjAPgren-Like Lacrimal Keratoconjunctivitis in Germ-Free Mice. ( 29438346 )
2018
40
Vernal keratoconjunctivitis. ( 29391772 )
2018
41
Outcomes and Rationale of Excision and Mucous Membrane Grafting in Palpebral Vernal Keratoconjunctivitis. ( 29040121 )
2018
42
Recombinant type Human mastadenovirus D85 associated with epidemic keratoconjunctivitis since 2015 in Japan. ( 29396992 )
2018
43
Nuclear parameters and chromatin remodeling in epithelial cells and lymphocytes from the palpebral conjunctiva of dogs with keratoconjunctivitis sicca. ( 29493861 )
2018
44
Investigation of the efficacy of alcohol-based solutions on adenovirus serotypes 8, 19 and 37, the common cause of epidemic keratoconjunctivitis, after an adenovirus outbreak occurred in the hospital. ( 29792970 )
2018
45
Molecular typing and whole genome next generation sequencing of human adenovirus 8 strains recovered from four 2012 outbreaks of keratoconjunctivitis in New York State. ( 29750363 )
2018
46
Optimising tear replacement rheology in canine keratoconjunctivitis sicca. ( 29303147 )
2018
47
Clinical trials with multiple endpoints can establish a correlation, but not (yet) causality, between dietary supplementation with omega-3 fatty acids and keratoconjunctivitis sicca. ( 29781353 )
2018
48
Clinical and virological analysis of epidemic keratoconjunctivitis caused by adenovirus type 54 in a regional ophthalmic clinic in Kyushu, Japan. ( 29593376 )
2018
49
Microvascular Submandibular Gland Transplantation for Severe Keratoconjunctivitis Sicca: A Single-Institution Experience of 56 Cases. ( 29864431 )
2018
50
Comparative Evaluation of Tacrolimus Versus Interferon Alpha-2b Eye Drops in the Treatment of Vernal Keratoconjunctivitis: A Randomized, Double-Masked Study. ( 29040120 )
2018

Variations for Keratoconjunctivitis

Expression for Keratoconjunctivitis

Search GEO for disease gene expression data for Keratoconjunctivitis.

Pathways for Keratoconjunctivitis

Pathways related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 AOC1 CCL11 CD46 CXCL8 ICAM1 IFNG
2
Show member pathways
13.86 CCL11 CCL17 CXCL8 IL13 IL2 IL3
3
Show member pathways
13.72 CCL11 CCL17 CXCL8 IFNG IL13 IL2
4
Show member pathways
13.57 CCL11 CCL17 CXCL8 ICAM1 IFNG IL13
5
Show member pathways
13.48 CCL11 CCL17 CXCL8 IL13 IL2 IL3
6
Show member pathways
13.44 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
7
Show member pathways
13.38 CCL11 CCL17 CXCL8 IL13 IL2 IL3
8
Show member pathways
12.96 IL2 IL3 IL4 NGF TNF
9 12.91 CXCL8 IFNG IL13 IL2 IL3 IL4
10
Show member pathways
12.8 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
11
Show member pathways
12.68 IFNG IL13 IL2 IL4 IL5 TNF
12
Show member pathways
12.68 CD46 CXCL8 ICAM1 IFNG IL13 IL2
13 12.65 CD46 IFNG IL2 IL3 IL4 TNF
14
Show member pathways
12.62 IL13 IL3 IL4 IL5 TNF
15
Show member pathways
12.6 ICAM1 IFNG IL2 IL3 IL4 TNF
16
Show member pathways
12.53 IFNG IL13 IL2 IL3 IL4 IL5
17
Show member pathways
12.49 IFNG IL2 IL4 IL5 TNF
18
Show member pathways
12.46 CCL11 CCL17 CXCL8 IFNG IL13 IL4
19
Show member pathways
12.4 ICAM1 IFNG IL2 IL4 TNF
20
Show member pathways
12.36 CXCL8 IFNG IL13 IL2 IL3 IL4
21
Show member pathways
12.28 CCL11 CXCL8 IFNG IL4 TNF
22 12.21 CXCL8 IL13 NGF TNF
23 12.14 CXCL8 ICAM1 IFNG IL2 IL4 TNF
24 12.12 IFNG IL2 IL3 IL4 IL5 TNF
25 12.1 CCL11 CXCL8 ICAM1 IL13 IL4 TNF
26
Show member pathways
12.09 IFNG IL13 IL4 TNF
27
Show member pathways
12.02 IFNG IL2 TNF
28
Show member pathways
12 IL13 IL2 IL5
29
Show member pathways
11.97 CCL11 CCL17 CXCL8
30 11.97 IL3 IL4 IL5 TNF
31
Show member pathways
11.95 IFNG IL2 IL4
32 11.94 CXCL8 ICAM1 IFNG TNF
33 11.94 CXCL8 ICAM1 IFNG IL13 IL2 IL4
34 11.92 CXCL8 IFNG IL3
35 11.9 IFNG IL13 IL2 IL4 IL5 TNF
36 11.89 CXCL8 ICAM1 TNF
37 11.87 CXCL8 IFNG TNF
38 11.87 CXCL8 ICAM1 TNF
39 11.85 IFNG IL2 IL3
40
Show member pathways
11.83 CXCL8 IFNG IL2 IL3 IL4 IL5
41
Show member pathways
11.82 CXCL8 ICAM1 IFNG IL2 TNF
42 11.81 CCL11 CXCL8 IL13 IL4 IL5 TNF
43 11.77 CCL11 CCL17 IL4 IL5
44 11.76 IFNG IL2 TNF
45 11.76 CCL11 CCL17 IFNG IL13 IL2 IL4
46
Show member pathways
11.71 CCL11 CCL17 CXCL8 ICAM1 IFNG IL13
47 11.68 CXCL8 ICAM1 IL13 IL4 TNF
48
Show member pathways
11.67 IFNG IL2 TNF
49 11.65 CXCL8 ICAM1 IFNG TNF
50 11.59 IFNG IL2 TNF

GO Terms for Keratoconjunctivitis

Cellular components related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 AOC1 CCL11 CCL17 CXCL8 IFNG IL13
2 extracellular space GO:0005615 9.5 AOC1 CCL11 CCL17 CXCL8 ICAM1 IFNG

Biological processes related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.88 CCL11 CCL17 ICAM1 TNF
2 positive regulation of gene expression GO:0010628 9.88 CD46 IFNG IL13 IL4 NGF TNF
3 MAPK cascade GO:0000165 9.87 IL2 IL3 IL5 TNF
4 inflammatory response GO:0006954 9.85 CCL11 CCL17 CXCL8 IL13 IL5 TNF
5 immune response GO:0006955 9.85 CCL11 CCL17 CXCL8 IFNG IL13 IL2
6 response to ethanol GO:0045471 9.83 ICAM1 IL13 IL2
7 response to virus GO:0009615 9.82 CCL11 IFNG TNF
8 cellular response to interferon-gamma GO:0071346 9.82 CCL11 CCL17 ICAM1
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.8 ICAM1 IL3 IL5
10 neutrophil chemotaxis GO:0030593 9.79 CCL11 CCL17 CXCL8
11 cellular response to tumor necrosis factor GO:0071356 9.78 CCL11 CCL17 CXCL8 ICAM1
12 positive regulation of inflammatory response GO:0050729 9.77 IL2 TNF TSLP
13 chemokine-mediated signaling pathway GO:0070098 9.75 CCL11 CCL17 CXCL8
14 positive regulation of T cell proliferation GO:0042102 9.73 CD46 IL2 IL4
15 cellular response to interleukin-1 GO:0071347 9.73 CCL11 CCL17 CXCL8 ICAM1
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 IFNG IL13 IL2 IL3 IL4 TSLP
17 positive regulation of nitric oxide biosynthetic process GO:0045429 9.71 ICAM1 IFNG TNF
18 microglial cell activation GO:0001774 9.67 IL13 TNF
19 negative regulation of endothelial cell apoptotic process GO:2000352 9.67 ICAM1 IL13 IL4
20 embryonic digestive tract development GO:0048566 9.66 CXCL8 TNF
21 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.65 IFNG TNF
22 regulation of regulatory T cell differentiation GO:0045589 9.65 IFNG IL2
23 positive regulation of immunoglobulin secretion GO:0051024 9.64 IL2 IL5
24 positive regulation of podosome assembly GO:0071803 9.63 IL5 TNF
25 positive regulation of regulatory T cell differentiation GO:0045591 9.63 CD46 IL2
26 positive regulation of B cell proliferation GO:0030890 9.62 IL13 IL2 IL4 IL5
27 positive regulation of isotype switching to IgG isotypes GO:0048304 9.61 IL2 IL4
28 cytokine-mediated signaling pathway GO:0019221 9.61 CCL11 CXCL8 ICAM1 IL13 IL2 IL3
29 positive regulation of interleukin-13 production GO:0032736 9.59 IL4 TSLP
30 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.55 ICAM1 TNF
31 negative regulation of complement-dependent cytotoxicity GO:1903660 9.52 IL13 IL4
32 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.51 IFNG TNF
33 positive regulation of vitamin D biosynthetic process GO:0060557 9.46 IFNG TNF
34 regulation of signaling receptor activity GO:0010469 9.4 CCL11 CCL17 CXCL8 IFNG IL13 IL2
35 positive regulation of cell proliferation GO:0008284 10 IFNG IL2 IL3 IL5 TSLP

Molecular functions related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.43 IL2 IL3 IL5
2 cytokine activity GO:0005125 9.36 CCL11 CCL17 CXCL8 IFNG IL13 IL2
3 growth factor activity GO:0008083 9.35 IL2 IL3 IL4 IL5 NGF
4 chemokine activity GO:0008009 9.33 CCL11 CCL17 CXCL8

Sources for Keratoconjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....